Treatment of glossodynia with olanzapine

Gick, Carrie L.; Mirowski, Ginat W.; Kennedy, J. S.; Bymaster, Frank P.

doi:10.1016/j.jaad.2004.02.016

Cited by 21 publications

(12 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3 BMS has also been successfully treated with olanzapine, which exerts its effects through antagonism at serotonin and dopamine receptors. 9 Neurological changes seen in BMS patients include change in the eye-blink reflex which appears to be related to longer disease duration. 10 Additionally, positron emission tomography seems to indicate decreased dopaminergic inhibition in BMS patients.…”

Section: Physiological Factorsmentioning

confidence: 99%

Burning mouth syndrome and psychological disorders

Abetz

Savage

2009

Australian Dental Journal

107

113

View full text Add to dashboard Cite

Burning mouth syndrome (BMS) is an oral dysaesthesia that causes chronic orofacial pain in the absence of a detectable organic cause. The aetiology of BMS is complex and multifactorial, and has been associated in the literature with menopause, trigger events and even genetic polymorphisms. Other studies have found evidence for mechanisms such as central and peripheral nervous system changes, with clinical and laboratory investigations supporting a neuropathologic cause. These physiological explanations notwithstanding, there is still much evidence that BMS aetiology has at least some psychological elements. Somatoform pain disorder has been suggested as a mechanism and factors such as personality, stress, anxiety, depression and other psychological, psychosocial and even psychiatric disorders play a demonstrable role in BMS aetiology and symptomatology. In order to treat BMS patients, both physiological and psychological factors must be managed, but patient acceptance of possible components of psychological disease basis is a major hurdle. Clinical signs of patient stress, anxiety or depression are a useful reinforcement of clinical discussions. The current paper proposes a number of clinical signs that may be useful for both clinical assessment and subsequent patient discussions by providing visible supportive evidence of the diagnosis.

show abstract

Section: Physiological Factorsmentioning

confidence: 99%

Burning mouth syndrome and psychological disorders

Abetz

Savage

2009

Australian Dental Journal

107

113

View full text Add to dashboard Cite

show abstract

“…The effectiveness of many pharmacological agents, including pregabalin, 18) topiramate, 19) duloxetine, 20) pramipexol, 21) and olanzapine, 22,23) has been reported in isolated cases or case series. In the present study, we reported the effectiveness of new pharmacologic agents that had not been discussed previously in the literature.…”

Section: Discussionmentioning

confidence: 99%

Retrospective Review of Effectiveness of Various Pharmacological Agents in Treating Burning Mouth Syndrome

Im¹,

Kim²,

Kim³

2016

Journal of Oral Medicine and Pain

View full text Add to dashboard Cite

Purpose: Burning mouth syndrome (BMS) is a chronic pain condition involving the oral and perioral regions, often characterized by a burning sensation and pain in elderly patients. In this study, we investigated the effectiveness of pharmacological agents for the treatment of BMS patients through a retrospective chart review. Methods:We enrolled 61 BMS subjects (57 females, 4 males; 66.4±10.9 years of age) from among consecutive patients treated pharmacologically from January 2014 to June 2015 at Chonnam National University Dental Hospital. Patients with secondary BMS associated with local factors were excluded. The treatment period, number of pharmacological agents tried, and effectiveness of the drugs administered to each subject were analyzed. Results:The mean treatment period for the management of BMS was 2.5 months. More than three agents were tried to control BMS symptoms in 17 subjects (27.9%); two agents were used in 10 subjects (16.4%), and a single agent in 24 subjects (39.3%). Clonazepam was prescribed most frequently and was effective at relieving symptoms in 30 of 39 subjects (76.9%). Paroxetine was moderately effective, relieving symptoms in 7 of 17 subjects (41.2%). Some of the subjects benefited from tricyclic antidepressants, gabapentin, and lipoic acid. A topical local anesthetic used to supplement other systemic agents had ameliorating effects in four of six subjects. Conclusions:Within the study limitations, clonazepam was the most effective drug and antidepressants were efficacious in some subjects for relieving the symptoms of BMS. These pharmacological agents could be considered as first-line drugs for the management of BMS.

show abstract

“…Neurogenic mechanisms for BMS are supported by literature demonstrating central and peripheral nervous system changes 3,4 . Investigations, such as biopsy, 5 examination of the eye blink reflex, 6 dopaminergic function, 7 drug therapy, 3,8 and salivary composition, 4 might support a neuropathological basis.…”

Section: Introductionmentioning

confidence: 93%